Arcutis Biotherapeutics
ARQT · Nasdaq · United States
Share price · ARQT
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ARQT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 6 Nov 2026-5.4%
- 5 Nov 2026-20.7%
- 19 Oct 2026+10.7%
Nothing announced by ARQT that day or the session before.
- 15 Oct 2026+10.2%
Nothing announced by ARQT that day or the session before.
- 9 Oct 2026+8.5%
- 16 Sep 2026+11.2%
Nothing announced by ARQT that day or the session before.
- 7 Aug 2026-4.3%
- 7 May 2026-14.5%
- 2 Mar 2026-8.2%
Nothing announced by ARQT that day or the session before.
- 27 Feb 2026-5.6%
Nothing announced by ARQT that day or the session before.
Share of unusual movement by asset
For each asset, the share of ARQT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | PDE4Small molecule | PsoriasisSeborrheic Dermatitis | |
| Approved | PDE4Small molecule | Atopic DermatitisPsoriasis | |
| Phase 1 | CD200RProtein / enzyme therapeutic | Atopic Dermatitis |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
April 2028 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $144M | $22M | $34M+ $226M short-term inv. | —$19M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $130M | $20M | $34M+ $204M short-term inv. | —$13M operating cash flow | report ↗ |
| 2026-Q1 | $105M | — | $224M | $11M | report ↗ |
| 2025-Q3 | $99M | $20M | $47M+ $144M short-term inv. | —-$1.8M operating cash flow | report ↗ |
| 2025-Q2 | $82M | $19M | $73M+ $118M short-term inv. | $16M$0.3M operating cash flow | report ↗ |
| 2025-Q1 | $64M | $18M | $54M+ $145M short-term inv. | $25M-$30M operating cash flow | report ↗ |
| 2024-Q3 | $45M | $20M | $135M+ $196M short-term inv. | $42M-$35M operating cash flow | report ↗ |
| 2024-Q2 | $31M | $19M | $85M+ $278M short-term inv. | $52M-$45M operating cash flow | report ↗ |
| 2024-Q1 | $22M | $23M | $191M+ $214M short-term inv. | $35M-$32M operating cash flow | report ↗ |
| 2023-Q3 | $38M | $26M | $108M+ $120M short-term inv. | $45M-$44M operating cash flow | report ↗ |
| 2023-Q2 | $4.8M | $25M | $106M+ $164M short-term inv. | $71M-$66M operating cash flow | report ↗ |
| 2023-Q1 | $2.8M | $35M | $82M+ $251M short-term inv. | $80M-$80M operating cash flow | report ↗ |
| 2022-Q3 | $0.7M | $70M | $83M+ $395M short-term inv. | $108M-$68M operating cash flow | report ↗ |
| 2022-Q2 | $0 | $38M | $63M+ $221M short-term inv. | $67M-$62M operating cash flow | report ↗ |
| 2022-Q1 | $0 | $41M | $71M+ $274M short-term inv. | $64M-$57M operating cash flow | report ↗ |
| 2021-Q3 | $0 | $41M | $53M+ $315M short-term inv. | $57M-$41M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $372M | $77M | $43M+ $178M short-term inv. | $4.0M-$5.6M operating cash flow | report ↗ |
For FY2025, Arcutis reported product revenue of $372.07M, up 123.4% YoY, with R&D spend of $77.05M, up 0.8% YoY. Cash and equivalents were $43.22M, and the company recorded a net loss of $16.14M.
Arcutis raised its full-year 2026 net product revenue guidance to $480M-$495M. Clinical updates included positive topline data from the INTEGUMENT-INFANT Phase 2 trial for ZORYVE cream 0.05% in atopic dermatitis, with an sNDA submission expected in Q2 2026; an accepted sNDA for ZORYVE cream 0.3% in plaque psoriasis with a PDUFA date of June 29, 2026; ongoing Phase 2 studies in vitiligo and hidradenitis suppurativa; and a planned Phase 1 study of ARQ-234. The company also announced expansion of its dermatology sales force, termination of its promotion agreement with Kowa, and positive operating cash flow in Q4 2025.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $167M | $76M | $72M+ $157M short-term inv. | $35M-$112M operating cash flow | report ↗ |
| 2023-FY | $60M | $111M | $89M+ $183M short-term inv. | $66M-$247M operating cash flow | report ↗ |
| 2022-FY | $3.7M | $182M | $55M+ $356M short-term inv. | $78M-$258M operating cash flow | report ↗ |
| 2021-FY | $0 | $146M | $98M+ $291M short-term inv. | $52M-$175M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 66 sales ($13.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-16 | Welgus Howard G. · director | Option exercise | 822 | $6.52 | $5K | Form 4 |
| 2026-11-16 | Welgus Howard G. · director | Option exercise | 1,018 | $7.51 | $8K | Form 4 |
| 2026-11-16 | Welgus Howard G. · director | Option exercise | 2,254 | $8.63 | $19K | Form 4 |
| 2026-11-16 | Welgus Howard G. · director | Open-market sale | 4,728 | $28.16 | $133K | Form 4 |
| 2026-11-16 | Welgus Howard G. · director | Option exercise (derivative) | 822 | — | — | Form 4 |
| 2026-11-16 | Welgus Howard G. · director | Option exercise (derivative) | 1,018 | — | — | Form 4 |
| 2026-11-16 | Welgus Howard G. · director | Option exercise (derivative) | 2,254 | — | — | Form 4 |
| 2026-11-13 | Watanabe Todd · director, See Remarks | Gift | 144,232 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 264 reporting institutions held 132.1M shares ($3.1B, 104.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | SUVRETTA CAPITAL MANAGEMENT, LLC | 12,327,000 | $290.4M |
| 2 | Frazier Life Sciences Management, L.P. | 9,874,511 | $232.6M |
| 3 | BlackRock, Inc. | 9,200,411 | $216.8M |
| 4 | Rubric Capital Management LP | 8,271,577 | $194.9M |
| 5 | STATE STREET CORP | 6,296,197 | $148.3M |
| 6 | Polar Capital Holdings Plc | 5,666,940 | $133.5M |
| 7 | JENNISON ASSOCIATES LLC | 4,980,770 | $117.3M |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 4,871,536 | $114.8M |
| 9 | GILDER GAGNON HOWE & CO LLC | 4,304,010 | $101.4M |
| 10 | MORGAN STANLEY | 4,218,931 | $99.4M |
| 11 | UBS Group AG | 3,329,224 | $78.4M |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 3,045,306 | $71.8M |
| 13 | D. E. Shaw & Co., Inc. | 2,496,222 | $58.8M |
| 14 | MARSHALL WACE, LLP | 2,431,778 | $57.3M |
| 15 | FRANKLIN RESOURCES INC | 2,297,943 | $54.1M |